Webinar: Cellular Thermal Shift Assays – bringing relevant target engagement to your drug discovery workflow

The Cellular Thermal Shift Assay (CETSA®) is an easy and proven method to demonstrate ligand-protein interactions in living cells and can be used without the need of any modifications to the ligand or protein. Quantification methods like PerkinElmer’s no-wash immunoassays Alpha or Homogenous Time Resolved Fluorescence (HTRF) can be subsequently applied to confirm biologically relevant findings.

Joe Shaw, Associated Principle Scientist at AstraZeneca, will present several case studies detailing how CETSA® technology has been implemented and utilised in drug discovery projects at AstraZeneca.

Following the presentation, there will be a panel of pharma thought leaders discussing CETSA® technology. Dr Ken Comess from Abbvie, Dr Joseph Shaw from AstraZeneca and Ruth Sommerse from Pfizer will come together and explore the impact of CETSA® NAVIGATE HT in drug discovery.

Are you sure?

Is you target compound really theraputic?

Speak to our experts

Learn how CETSA® can enable your project by talking to one of our Drug Discovery experts.